Massachusetts pharmacy board head fired after meningitis outbreak

BOSTON Wed Nov 7, 2012 5:25pm EST

Framingham police officers keep watch as federal agents search the New England Compounding Center company in Framingham, Massachusetts October 16, 2012. REUTERS/Dominick Reuter

Framingham police officers keep watch as federal agents search the New England Compounding Center company in Framingham, Massachusetts October 16, 2012.

Credit: Reuters/Dominick Reuter

Related Topics

BOSTON (Reuters) - Authorities fired the director of the Massachusetts Board of Pharmacy after he failed to investigate a complaint against New England Compounding Center, the company at the center of a deadly U.S. meningitis outbreak, state officials said on Wednesday.

NECC is linked to a meningitis outbreak that has infected more than 400 people and caused 31 deaths.

Massachusetts officials said they uncovered a complaint against NECC by Colorado pharmacy regulators just months before the outbreak. The complaint, which said NECC was distributing drugs without patient-specific prescriptions, was forwarded on July 26 to James Coffey, director of the Massachusetts pharmacy board.

Coffey failed to order an investigation or take any other action on the Colorado complaint, the Massachusetts Department of Public Health's interim commissioner, Dr. Lauren Smith, said in a statement.

In the years before the outbreak, NECC escaped harsh punishment from the Massachusetts pharmacy board, raising questions about oversight of the customized drug mixing industry, state records released last month show.

Smith said Coffey has been terminated and the pharmacy board's counsel, Susan Manning, has been placed on administrative leave pending the final conclusions of the investigation.

"It is incomprehensible that Mr. Coffey and Ms. Manning did not act on the Colorado complaint given NECC's past, and their responsibility to investigate complaints," Smith said in a statement. "Following the outbreak, staff also failed to disclose the existence of Colorado's complaint to leadership at" the Department of Public Health.

Coffey was not immediately available for comment.

The Colorado State Board of Pharmacy shared information that showed NECC had distributed many drugs to many hospitals in Colorado between 2010 and 2012, but without patient-specific prescriptions. That was a violation of NECC's Colorado and Massachusetts licenses, according to Smith's statement. NECC was not immediately available for comment.

In 2011, during a routine inspection, Colorado inspectors found that NECC had participated in the unregistered/unlicensed distribution of prescription drugs in Colorado. As a result, Colorado issued a cease-and-desist order against NECC in April 2011.

"I find the actions of NECC reprehensible," Smith said in the statement. "We have the right to expect that all companies producing medication for use in delivering health care to comply with laws designed to protect patient safety. But I also expect the staff charged with oversight to perform their duties to the highest standards. That failed to happen here."

(Reporting by Tim McLaughlin; Editing by Gary Hill and Leslie Adler)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
tyg wrote:
Anybody getting fired at FDA or DHHS? What were FDA’s actions after warning the company? Who did nothing at FDA? The public is not holding FDA accountable for the amount of money their people are getting. Not only should the public find out what did FDA and the Mass. board of health not do, but the public should find out how many people get promoted, paid bonuses, lawyer bonuses, medical bonuses, as a result of at least 31 people dying and over 400 people sickened.

Meaningless congressional hearings to slap FDA leadership and then raise their pay or give them higher positions while they are still alive, while the dead are gone. Exactly how many dead Americans does the US need to do anything? 1 dead congressman’s daughter, 2 dead FDA or Massachusetts leader’s sons, or 30 dead average folk?

If these were American victims in a foreign country, it would be a national crisis. The dead and sick are just the cost of doing business with the pharmaceutical industry. Since compounders do not pay a user fee to FDA maybe it is not as important to keep the public safe from them as all the rich firms that do and are paying FDA customers. The compounding actions are “inevitable” because FDA doesn’t have any authority or money to pay their drug and law leadership.

Nov 09, 2012 12:58am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

Pictures